can glp 1 hurt your kidneys GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease GLP-1 and the kidney: from

More recent evidence is expanding their benefits to heart failure with preserved ejection fraction and clinically important renal outcomes in patients with and without diabetes

Dr Gregom Sng and Dr Chew Chun Yang from Parkway Shenton explain whos suitable, how these medications work, and what results to expect.

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium.“Psoriatic arthritis seems to have a special place for increased risk for obesity,&rdquo

Purpose of Review: This article summarizes the medical management of obesity with an emphasis on incretin-based therapeutics that target the neuro-hormonal basis of obesity.Recent Findings: Medications that mimic the effect of incretins, a group of peptide hormones released in response to nutrient intake that regulate appetite, result in potent and durable weight loss

As presented at the American Diabetes Association Meeting: this randomized phase 2b trial in 230 adults with overweight or obesity shows that aleniglipron, an oral small-molecule GLP1-RA, led to up to 11.3% body-weight loss compared with placebo after 36 weeks of treatment.